donwloadimg

Download App

Log in to access Online Inquiry
Multi-dimentional Analyses
Company Valuation Capital Tracking Short Selling Data

VNDA Vanda Pharmaceuticals

10.700
-0.070-0.65%
Close 06/24 16:00 ET
10.70000.00%
Post Mkt Price 06/24 16:16 ET
High
10.920
Open
10.840
Turnover
6.60M
Low
10.550
Pre Close
10.770
Volume
614.68K
Market Cap
604.44M
P/E(TTM)
33.44
52wk High
21.863
Shares
56.49M
P/E(Static)
18.45
52wk Low
9.240
Float Cap
553.89M
Bid/Ask %
60.00%
Historical High
33.440
Shs Float
51.77M
Volume Ratio
0.68
Historical Low
0.450
Dividend TTM
--
Div Yield TTM
750
P/B
1.20
Dividend LFY
--
Div Yield LFY
7009.35%
Turnover Ratio
1.19%
Amplitude
3.44%
Avg Price
10.735
Lot Size
1
Float Cap
553.89M
Bid/Ask %
60.00%
Historical High
33.440
Shs Float
51.77M
Volume Ratio
0.68
Historical Low
0.450
Dividend TTM
--
P/B
1.20
Dividend LFY
--
Turnover Ratio
1.19%
Amplitude
3.44%
Avg Price
10.735
Lot Size
1
Price Forecast

No Data

News

Comment

Company Overview More
Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs. The company’s marketed products include HETLIOZ for the treatment of non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia. Its products under development include HETLIOZ (tasimelteon) for the treatment of jet lag disorder, smith-magenis syndrome, pediatric Non-24, autism spectrum, and delayed sleep phase disorder; Fanapt (iloperidone) for the treatment of bipolar disorder and a long acting injectable formulation program for the treatment of schizophrenia; and Tradipitant (VLY-686), a small molecule neurokinin-1 receptor (NK-1R) antagonist, for the treatment of atopic dermatitis, gastroparesis, and motion sickness. The company’s products under development also comprise VTR-297, a small molecule histone deacetylase inhibitor for the treatment of hematologic malignancies and with potential use as a treatment for various oncology indications; VQW-765, a small molecule nicotinic acetylcholine receptor partial agonist for the treatment of psychiatric disorders; a portfolio of cystic fibrosis transmembrane conductance regulator activators and inhibitors for the treatment of dry eye and ocular inflammation, as well as BPO-27 for the treatment of secretory diarrhea disorders, including cholera; and VHX-896, the active metabolite of iloperidone. It markets its products in the United States, Europe, and Israel. Vanda Pharmaceuticals Inc. was incorporated in 2002 and is headquartered in Washington, the District of Columbia.
CEO: Polymeropoulos M.D., Mihael H.
Market: NASDAQ
Hot List
TradeSearchNews
SymbolLatest price%Chg

Loading...